Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (6.897%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.50
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing of Shares & admission to Official List LSE

9 Nov 2015 07:00

RNS Number : 9302E
Silver Falcon PLC
09 November 2015
 

9th November 2015

 

Silver Falcon PLC

(the "Company")

 

Placing of 43,300,000 Ordinary Shares and admission to the Official List of the London Stock Exchange.

 

Silver Falcon PLC (LSE: SILF) today announces the successful, oversubscribed placing of 43,300,000 Ordinary Shares at a placing price of £0.03 per New Ordinary Share and admission to the Official List of the London Stock Exchange of 64,900,000 Ordinary Shares and to trading on the London Stock Exchange's main market for listed securities.

 

The Company has been formed for the purpose of acquiring a company or business. The Company's efforts in identifying a prospective target company or business will not be limited to a particular industry or geographic region, but the Directors intend to focus on the Financial Services sector and more specifically the FinTech sector in seeking acquisition targets, given their significant experience.

 

The Directors of the Company are Geoffrey Dart, Peter Redmond and Adrian Beeston, a highly knowledgeable and experienced group of professionals with extensive experience of making successful international acquisitions and the ability to return value to investors and introduce and complete operational improvements to companies.

 

It is expected that Admission will become effective and that unconditional dealings will commence at 8.00 a.m. on 9 November 2015.

 

Geoffrey Dart, Chairman, commented:

"Silver Falcon has been formed for the purpose of making acquisitions in the Financial Services Sector. Our Directors have significant track records in sourcing and executing successful acquisitions and returning value to shareholders and have a particular interest in the FinTech sub-sector. We look forward to acquiring companies that generate value for our shareholders through operational improvements, along with potential further complementary acquisitions.

 

"We are delighted that the placing was oversubscribed which indicates the confidence placed in the future of the company."

 

 

 

Ends

 

 

For more information contact:

 

Silver Falcon PLC Tel: +44 (0) 20 3757 4980

Geoffrey Dart C/O Camarco

 

Camarco Tel: +44 (0) 20 3757 4980

Billy Clegg/ Jennifer Renwick

 

 

 

 

 

Notes to Editors

 

Shareholders

Major Shareholders of the Company as at Admission are:

 

Shareholder

No. of Ordinary Shares

Percentage of issued ordinary share capital

Optiva Securities Limited (1)

5,000,000

7.70

Geoffrey Dart (2)

4,800,000

7.39

Peter Redmond (3)

3,600,000

5.54

Adrian Beeston

3,350,000

5.16

 

 

(1) Optiva Securities Limited holds these shares through JIM Nominees Limited.

(2) Geoffrey Dart holds 2,300,000 shares through Chesterfield Capital Limited, of which he is the ultimate beneficial owner and 2,500,000 shares through Black Eagle Capital, of which he holds 45.25 per cent.

(3) Peter Redmond holds these shares through Catalyst Corporate Consultants Limited, a company of which he is the sole shareholder.

 

Directors

Geoffrey Dart

Geoffrey Dart is a merchant banker with over 35 years of experience of fund raising and listing transactions. In 1990 he was appointed to the board of Harrell Hospitality Inc, a hotel management and development company, after he structured and completed its reverse takeover by a US-listed shell company. In 2003, as chairman of Energy Technique Plc (a Main Market company) Geoffrey oversaw the re-structuring and re-capitalisation of the company. Also in 2003, as a founder and an executive director of London and Boston Investments Plc (an AIM-listed company), Geoffrey was responsible for M&A activity for the company. In 2010, Geoffrey joined the board of Hayward Tyler Limited, the specialist pump manufacturer and after raising equity and debt funding, completed the Main Market listing of the company and thereafter took on particular responsibility for the group's Chinese operations and completed a successful re-structuring of those operations.

 

Peter Redmond

Peter Redmond is a corporate financier with some 30 years' experience in corporate finance and venture capital. He has acted on and assisted a wide range of companies to attain a listing over many years, on the Unlisted Securities Market, the Full List and AIM, whether by IPO or in many cases via reversals, across a wide range of sectors, ranging from technology through financial services to natural resources and, in recent years has done so as a director of the companies concerned. He has been active over many years in corporate rescues and reconstructions on AIM and in reverse transactions into a range of investing companies. He was a founder director of Cleeve Capital plc (now Satellite Solutions Worldwide Group plc) and Mithril Capital plc, both of which were admitted to the Standard List of the London Stock Exchange, and took a leading role in the reconstruction and refinancing of AIM-quoted Kennedy Investments and 3Legs Resources plc.

 

Adrian Richard Thorpe Beeston

Adrian founded Thorpe-Beeston Investments Ltd ("TBIL") in 2002. TBIL specializes in the financing and structuring of small to medium size businesses, and the flotation of these companies on the American Stock Exchange, AIM Exchange and TSX Venture Exchange. Previous to this, Adrian was at Altium Capital, a major pan-European corporate finance house, where he focused primarily on the raising of private equity. Adrian has worked extensively in small to mid size businesses, financing and working with over 20 companies in the last 5 years. Other work has included implementation of corporate structure, human resources planning, corporate governance policies and providing finance once these cornerstones of a business are in place.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMGMVVNGKZM
Date   Source Headline
9th Mar 20212:00 pmRNSPrice Monitoring Extension
9th Mar 202111:00 amRNSPrice Monitoring Extension
9th Mar 20217:00 amRNSDirector/PDMR Shareholding
8th Mar 20217:00 amRNSH.C. Wainwright Investment Conference
3rd Mar 20217:00 amRNSHEMO-CAR-T Update
26th Feb 202110:05 amRNSTotal Voting Rights
25th Feb 20214:56 pmRNSConversion of Convertible Loan Notes
15th Feb 20214:41 pmRNSSecond Price Monitoring Extn
15th Feb 20214:36 pmRNSPrice Monitoring Extension
10th Feb 20217:00 amRNSAllotment of Shares
3rd Feb 20217:01 amRNSDraw Down Under Financing Facility Agreement
29th Jan 20212:24 pmRNSPublication of Prospectus
13th Jan 20217:00 amRNSUpdate on CDX Antibody Development
6th Jan 20213:53 pmRNSResult of General Meeting
5th Jan 20217:00 amRNSCAR-T Master Translational Agreement with Penn
8th Dec 20207:00 amRNSChange to Date of General Meeting
2nd Dec 20204:41 pmRNSSecond Price Monitoring Extn
2nd Dec 20204:36 pmRNSPrice Monitoring Extension
2nd Dec 202011:06 amRNSSecond Price Monitoring Extn
2nd Dec 202011:01 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSPosting of Circular
18th Nov 20204:41 pmRNSSecond Price Monitoring Extn
18th Nov 20204:36 pmRNSPrice Monitoring Extension
18th Nov 20202:06 pmRNSSecond Price Monitoring Extn
18th Nov 20202:01 pmRNSPrice Monitoring Extension
18th Nov 202010:39 amRNSFinancing Facility of up to £60 Million
27th Oct 20207:00 amRNSCDX Development Agreement Further Extension
19th Oct 20207:00 amRNSPresentation at the American Society of Hematology
6th Oct 20207:00 amRNSSAFE-HEMO-CAR-T Effective against AML in vitro
30th Sep 20207:00 amRNSInterim Results for the period ended 30 June 2020
22nd Sep 202012:52 pmRNSFurther re. Grant of Options
10th Sep 20204:40 pmRNSSecond Price Monitoring Extn
10th Sep 20204:35 pmRNSPrice Monitoring Extension
26th Aug 20202:06 pmRNSSecond Price Monitoring Extn
26th Aug 20202:00 pmRNSPrice Monitoring Extension
25th Aug 20204:40 pmRNSSecond Price Monitoring Extn
25th Aug 20204:35 pmRNSPrice Monitoring Extension
21st Aug 20209:52 amRNSGrant of Options
14th Aug 20207:00 amRNSPresentations at Cancer Immunotherapy Symposia
11th Aug 20207:00 amRNSCAR-T Agreement with University of Pennsylvania
31st Jul 20207:00 amRNSBroker's Research Note
20th Jul 20204:40 pmRNSSecond Price Monitoring Extn
20th Jul 20204:35 pmRNSPrice Monitoring Extension
20th Jul 20202:05 pmRNSSecond Price Monitoring Extn
20th Jul 20202:00 pmRNSPrice Monitoring Extension
14th Jul 202011:00 amRNSPrice Monitoring Extension
14th Jul 20209:06 amRNSSecond Price Monitoring Extn
14th Jul 20209:00 amRNSPrice Monitoring Extension
13th Jul 20204:36 pmRNSPrice Monitoring Extension
13th Jul 20203:16 pmRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.